Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer



Status:Active, not recruiting
Conditions:Liver Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:19 - Any
Updated:8/16/2018
Start Date:July 16, 2012
End Date:July 2020

Use our guide to learn which trials are right for you!

A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)

The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and
effective treatment option for preventing liver cancer in high risk patients following liver
transplantation. Liver transplantation is a treatment option for liver cancer patients, but
despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not
known whether sorafenib is effective in preventing cancer recurrence in high risk patients
following liver transplantation

PRIMARY OBJECTIVES:

I. Two-year recurrence free survival (RFS).

SECONDARY OBJECTIVES:

I. One-year recurrence free survival. II. Overall survival (OS). III. Safety. IV. Impact of
drug-drug interactions (i.e. immunosuppression agents). V. Impact of biomarkers
(alpha-fetoprotein [AFP], protein-induced by vitamin K absence or antagonist II [PIVKA II]).

VI. Effects of therapy on wound healing. VII. Impact of hepatitis C viral recurrence.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sorafenib tosylate orally (PO) twice daily (BID).

ARM II: Patients receive placebo PO BID.

In both arms treatment continues for 24 months in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for 2 years.

Inclusion Criteria:

- Patients must have hepatocellular carcinoma (HCC) with one of the following on
explant: microvascular/macrovascular invasion, tumor outside of Milan criteria, poor
tumor differentiation; patients with macrovascular invasion on explant pathology will
be stratified

* Additionally, the following will be included

** Patients with elevated surrogate markers (AFP > 500 or PIVKA > 400) pre transplant
and with biopsy proven HCC prior to orthotopic liver transplantation (OLT) or on
explant

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

- Patients with a life expectancy > 12 weeks

- Patients must have completed prednisone taper within 6 weeks post OLT

- Patients must be enrolled between 6 to 12 weeks post OLT

- Cadaveric donors only (no living donor liver transplantation [LDLT] or donor after
cardiac death transplantation [DCDT])

- No sorafenib prior to inclusion in the study

- Platelet count > 50 x 10^9/L

- Hemoglobin >= 8.5 g/dL

- Total bilirubin =< 5 mg/dL

- Alanine transaminase (ALT) and aspartate aminotransferase (AST) =< 5 x upper limit of
normal

- Amylase and lipase =< 1.5 x the upper limit of normal

- Serum creatinine < 2 x the upper limit of normal

- Prothrombin time (PT) =< 6 seconds or international normalized ratio (INR) =< 2.3

- AFP > 500 (pre-transplant)

- PIVKA > 400 (pre-transplant)

- Patient has not received prior anti-angiogenic therapy, systemic targeted agents or
systemic chemotherapy

* Prior surgical resection, chemoembolization or other local therapy prior to
transplant is permitted

- Women of childbearing potential must have a negative serum pregnancy test performed
within 7 days prior to the start of study drug; post-menopausal women (defined as no
menses for at least 1 year) and surgically sterilized women are not required to
undergo a pregnancy test

- Patients (men and women) of childbearing potential must agree to use adequate
contraception beginning at the signing of the informed consent form (ICF) until at
least 30 days after the last dose of study drug; the definition of adequate
contraception will be based on the judgment of the principal investigator or a
designated associate

- Patient must be able to swallow and retain oral medication

- Patient must exhibit the ability to understand and willingness to sign a written
informed consent regarding the study and alternative treatments

Exclusion Criteria:

- Significant ongoing immunologic rejection based on pathology and clinical diagnosis
(from time of transplant until randomization)

- Use of T cell depleting agents for prevention or treatment of rejection at any point
prior to or after enrollment in the study

- Patient with documented evidence of metastatic disease

- 100% tumor necrosis on explant pathology

- Use of mammalian target of rapamycin (mTOR) inhibitors prior to transplant and as
post-transplant immunosuppression

- Use of alemtuzumab

- Living donor liver transplant (LDLT) or donation after cardiac death transplant (DCDT)

- Human immunodeficiency virus (HIV) positive patients

- Hepatitis C virus (HCV) recurrence at the time of randomization

- Use of direct acting antivirals for HCV recurrence

- Requirement of re-transplantation for primary non function

- Uncontrolled hypertension, defined as systolic blood pressure > 140 mmHg or diastolic
pressure > 90 mmHg, despite optimal medical management

- Active or clinically significant cardiac disease including:

- Congestive heart failure - New York Heart Association (NYHA) > class II

- Coronary artery disease

- Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or
digoxin

- Unstable angina or new-onset angina within 3 months before randomization, or
myocardial infarction (MI) within 6 months before randomization

- Clinically active serious infection documented by positive cultures or an incomplete
course of treatment for bacteremia or fungemia

- Evidence or history of bleeding diathesis or coagulopathy

- Patients with any pulmonary hemorrhage/bleeding event grade 2 or higher within 4 weeks
before randomization

- Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular
accident (including transient ischemic attacks [TIAs]) within 6 months before
randomization

- Prior use of raf-kinase inhibitors (sorafenib), vascular endothelial growth factor
(VEGF) inhibitors, mitogen-activated protein kinase
(MAPK)/extracellular-signal-related kinase (ERK) kinase (MEK) inhibitors, or farnesyl
transferase inhibitors

- Patients using cytochrome P450 3A4 (CYP3A4) inducers (eg, phenytoin, carbamazepine,
phenobarbital, St. John's Wort dexamethasone) at a dose of greater than 16 mg daily,
or rifampin and/or rifabutin within 28 days before randomization

- Patients with non-HCC malignancy except those with DCIS (ductal carcinoma in situ),
cervical cancer in-situ, basal cell or superficial bladder tumor; patients surviving a
cancer that was curatively treated and without evidence of recurrence for more than 3
years before randomization are allowed

- Presence of a non-healing wound, non-healing ulcer, or bone fracture

- Known or suspected allergy or hypersensitivity to any of the study drugs, study drug
classes, or excipients of the formulations given during the course of this trial

- Any malabsorption condition

- Women who are pregnant or breast-feeding

- Inability to comply with the protocol and/or not willing or not available for
follow-up assessments

- Patients with fibrolamellar HCC, cholangiocarcinoma, and combined
HCC-cholangiocarcinoma

- Any condition which, in the investigator's opinion, makes the patient unsuitable for
trial participation

- Prior use of any systemic chemotherapy for HCC

- Prior use of systemic investigational agents for HCC

- Prior use of raf-kinase inhibitors (sorafenib), VEGF inhibitors, MEK inhibitors or
farnesyl transferase inhibitors

- Use of biologic response modifiers, such as granulocyte colony-stimulating factor
(G-CSF), will not be permitted within 3 weeks prior to study entry; G-CSF and other
hematopoietic growth factors may be used in the management of acute toxicity, such as
febrile neutropenia, when clinically indicated or at the discretion of the
investigator; however, they may not be administered to prevent a dose reduction;
patients taking chronic erythropoietin are permitted, provided no dose adjustment is
undertaken within 1 month prior to randomization or during the study

- Autologous bone marrow transplant or stem cell rescue within four months of start of
study drug

- Concomitant treatment with rifampin and St. John's wort

- Concomitant oral mTOR inhibitor treatment

- Use of direct acting antivirals for HCV recurrence

- Use of T-cell depleting agents

- Use of alemtuzumab

- Anticoagulation, as described below, is allowed:

- Vitamin-K antagonists (e.g., warfarin)

** Low dose warfarin (1 mg orally, once daily) with PT-INR =< 1.5 x ULN is
permitted; patients taking concomitant warfarin should be monitored regularly for
changes in PT, PT-INR or clinical bleeding episodes

- Low dose aspirin (=< 100 mg daily).

- Heparins and heparinoids Use of any other investigational drug
We found this trial at
21
sites
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Principal Investigator: Sunil Geevarghese
Phone: 615-936-8640
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Stephen Hanish
Phone: 404-712-8890
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Andrew Cameron
Phone: 410-614-5700
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Goran Klintmalm
Phone: 214-820-2060
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Abhinav Humar
Phone: 412-692-4184
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
Principal Investigator: Shawn Pelletier
Phone: 734-936-8363
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Birmingham, Alabama 35294
Principal Investigator: Derek A. Dubay, M.D.
Phone: 205-996-5970
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Elizabeth Pomfret
Phone: 781-744-2500
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Cherry Hill, New Jersey 08034
Principal Investigator: Kim M. Olthoff
Phone: 215-662-6136
?
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Michael Abecassis
Phone: 312-695-0359
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Charles Miller
Phone: 216-445-2381
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Denver, Colorado 80210
Principal Investigator: Igal Kam
Phone: 702-848-0833
?
mi
from
Denver, CO
Click here to add this to my saved trials
Hartford, Connecticut 06112
Principal Investigator: Sander Florman
Phone: 212-659-8313
?
mi
from
Hartford, CT
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Rafik Mark Ghobrial
Phone: 713-441-6935
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Ronald Busuttil
Phone: 310-825-5318
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Ian Carmody
Phone: 504-842-5161
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
550 1st Ave
New York, New York 10016
(212) 263-7300
Principal Investigator: Lewis Teperman
Phone: 212-263-8360
New York University Langone Medical Center NYU NYU Langone Medical Center, a world-class, patient-centered, integrated,...
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: Tomoaki Kato
Phone: 212-305-8936
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73112
Principal Investigator: John Duffy
Phone: 405-949-3349
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Principal Investigator: Alan Langnas
Phone: 402-559-8390
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
3700 O Street Northwest
Washington, District of Columbia 20057
Principal Investigator: Kirti Shetty
Phone: 202-444-3704
?
mi
from
Washington,
Click here to add this to my saved trials